Market Overview

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James
Related QDEL
8 Biggest Price Target Changes For Tuesday
Benzinga's Top Upgrades, Downgrades For December 11, 2018

Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL)'s shares are not fully reflecting the company's growth potential and likely positive estimate revision bias, according to Raymond James. 

The Analyst

Raymond James analyst Nicholas Jansen upgraded shares of Quidel from Outperform to Strong Buy and increased the price target from $55 to $69.

The Thesis

After meetings with Quidel management at the 39th Annual Raymond James Institutional Investors Conference, Jansen said he identified the following as near-term catalysts and long-term opportunities. 

Near-Term Catalysts

  • Strong Q1 results: A better-than-thought Q1 flu season and strength in Sofia 2 and Solana placements are likely to help the company achieve revenue growth of 25 percent in Q1 compared to earlier expectations of 10-15 percent growth, the analyst said. Quidel's reference to its adjusted EBITA guidance as the "baseline" in the event of a normal flu season, suggesting likely upside, Jansen said.
  • Analyst day scheduled for April: Raymond James expects Quidel will provide a long-term product roadmap and go deeper into its growth drivers at the event, which could serve as a catalyst.

Long-Term Opportunities

  • The underappreciated installed base growth for the Sofia and Solana diagnostic testing platforms is becoming more valuable as the test menu expands
  • Raymond James said it has has increasing confidence in the Triage integration and additional revenue and cost synergy opportunities.
  • A long-term opportunity exists to cross-sell Quidel's product suite into new global commercial infrastructure, and the company has the potential for additional tuck-in M&A.

The Price Action

Quidel shares are up about 124 percent over the past year.

The stock was surging 4.59 percent to $49.03 at the time of publication Thursday afternoon. 

Related Links:

Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for QDEL

Dec 2018Raymond JamesMaintainsStrong BuyStrong Buy
Dec 2018Craig-HallumDowngradesBuyHold
Dec 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for QDEL
View the Latest Analyst Ratings

Posted-In: flu influenzaAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (QDEL)

View Comments and Join the Discussion!

Latest Ratings

EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Thor's 'Solid Quarter' Not Strong Enough For This Analyst To Turn Bullish

Stifel: Wynn's Quarter-To-Date Results 'Impressive,' But 'Considerable' Overhang Tied To Former CEO Remains